Results 301 to 310 of about 2,086,080 (370)
Some of the next articles are maybe not open access.
Journal of Clinical Oncology, 2019
207 Background: In patients previously treated for aHCC, cabozantinib (cabo) led to longer overall survival and progression-free survival vs placebo (pbo) in the randomized, phase 3 CELESTIAL trial (NCT01908426; N = 707).
G. Abou-Alfa +11 more
semanticscholar +1 more source
207 Background: In patients previously treated for aHCC, cabozantinib (cabo) led to longer overall survival and progression-free survival vs placebo (pbo) in the randomized, phase 3 CELESTIAL trial (NCT01908426; N = 707).
G. Abou-Alfa +11 more
semanticscholar +1 more source
Medical Care, 2018
Background: Although the life expectancy for the US population has increased, a high proportion of this population has lived with ≥1 chronic conditions.
Haomiao Jia +7 more
semanticscholar +1 more source
Background: Although the life expectancy for the US population has increased, a high proportion of this population has lived with ≥1 chronic conditions.
Haomiao Jia +7 more
semanticscholar +1 more source
Abstract The concept of quality-adjusted life years (QALY) is explained, with the approaches to measuring and problems with QALYs highlighted.
Phil Ambery +2 more
openaire +2 more sources
Phil Ambery +2 more
openaire +2 more sources
Quality‐adjusted life years: origins, measurements, applications, objections
Australian Journal of Public Health, 1993Abstract: Quality‐adjusted life years or QALYs are used to combine, in a single measure, information about the quantity and quality of life produced by a health intervention. They have been used as outcome measures in clinical trials and in cost‐effectiveness analyses. This paper describes how QALYs are assessed and how they are used.
Schwartz, Steven +2 more
openaire +3 more sources
Not all “quality-adjusted life years” are equal
Journal of Clinical Epidemiology, 2007There is evidence that utility elicitation methods used in the calculation of quality-adjusted life years (QALYs) yield different results. It is not clear how these differences impact economic evaluations.Using a mathematical model incorporating data on efficacy, costs, and utility values, we simulated the experiences of 100,000 hypothetical rheumatoid
C A, Marra +8 more
openaire +2 more sources
Cost-Utility Analysis and Quality Adjusted Life Years
Journal Of Pain & Palliative Care Pharmacotherapy, 2005Cost utility analysis is a form of cost-effectiveness analysis in which outcomes are adjusted for quality and quantity of life. This type of analysis is used widely in Europe and is being used increasingly in the United States. This article provides an overview of cost utility analysis and quality adjusted life years, a commonly used effectiveness ...
Vijay N, Joish, Gary M, Oderda
openaire +2 more sources
Methods for quality adjustment of life years
Social Science & Medicine, 1992Several valuation techniques are in use for quality adjusting life years in cost utility analysis. The paper gives an overview of the variability in results. A close inspection of a number of instruments with respect to their theme, instructions, decision framing and the phrasing of questions make many of the observed differences in results ...
openaire +2 more sources
quality-adjusted life-years (QALY)
2009syn. healthy-year equivalent (HYE); QALYs are calculated by multiplying the time spent in each health state by the value assigned to the particular health state; to calculate QALYs, numerical judgments of the desirability of various outcomes must be determined; these values are called “utilities” (with values between 0-death and 1-perfect health; very ...
openaire +1 more source